EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 weeks Safety data remains consistent with the known EYLEA HD and EYLEA safety profiles Supplementary biologics license [...]

Primary endpoint met, demonstrating a 21% slowing (p<0.001) in the growth rate of atrophic retinal lesions compared to the untreated arm; 28% reduction (p<0.001) using observed atrophic area. Patients receiving gildeuretinol showed 80% slower loss of retinal sensitivity compared to [...]

August 18, 2023 at 6:35 PM EDT Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer injections First and only treatment [...]

August 10, 2023 at 7:00 AM EDT TWO-YEAR PULSAR TRIAL RESULTS FOR AFLIBERCEPT 8 MG DEMONSTRATE DURABLE VISION GAINS AT EXTENDED DOSING INTERVALS IN WET AGE-RELATED MACULAR DEGENERATION 88% of all aflibercept 8 mg patients were on a ≥12-week dosing [...]

WALTHAM, Mass., July 30, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from the GALE extension study following 30 months of continuous treatment with SYFOVRE® (pegcetacoplan injection), the first and only FDA approved treatment for geographic atrophy [...]

February 23, 2023 at 7:00 AM EST AFLIBERCEPT 8 MG BLA FOR TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION AND DIABETIC MACULAR EDEMA ACCEPTED FOR FDA PRIORITY REVIEW BLA supported by two pivotal trials demonstrating non-inferior vision gains to EYLEA® (aflibercept) Injection, [...]

New data from a phase 3 trial measuring Roche’s Vabysmo versus Regeneron and Bayer’s Eylea in retinal vein occlusion (RVO) shows that more patients on Vabysmo had an absence of blood vessel leakage in the retina. While this pre-specified exploratory endpoint helps [...]

The Support Sight Foundation and founder Dawn Prall were so excited to be featured on the podcast Healthcare on the Horizon. In this podcast, Dawn talks about the prevalence of macular degeneration. Take a listen below!   Hi everyone. Today [...]

WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company has submitted a New Drug Application (NDA) to the United States Food and Drug [...]

Modus Outcomes, a scientific research company, will be doing a global survey later this year for the MOSAIC study. The study explores people’s experiences with geographic atrophy (GA), which is also known as advanced dryage-related macular degeneration (AMD). We are [...]